Particle.news
Download on the App Store
4 ARTICLES
·
yesterday

Astrocyte-Derived Peptide Achieves Nausea-Free Weight Loss in Animal Models

CoronationBio plans human trials in 2026 after TDN injections suppressed appetite in animals without causing nausea

false-color microscopic image of the hindbrain shows support cells (highlighted in green, red, yellow, and purple) that naturally produce appetite-suppressing molecules. Researchers at Syracuse University are targeting these cells to develop weight loss drugs that avoid the nausea and vomiting commonly seen with GLP-1 treatments.

Overview

  • Researchers identified octadecaneuropeptide (ODN) as a natural appetite suppressant produced by astrocytes in the hindbrain.
  • A modified peptide, tridecaneuropeptide (TDN), was engineered for systemic injection to mimic ODN’s effects without brain surgery.
  • In studies with obese mice and musk shrews, TDN administration led to significant weight loss and enhanced insulin response without triggering nausea or vomiting.
  • TDN works by engaging downstream astrocyte pathways rather than neurons, potentially sidestepping gastrointestinal side effects common to GLP-1 drugs.
  • CoronationBio has been launched to advance ODN derivatives into human trials slated for 2026 and 2027.